Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
Investor's Business Daily on MSN37m
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...
The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurogenerative disease, but is ...
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Here is a GMC Sierra owner who has a warning for truck buyers. Her Sierra truck looks great on the outside and inside, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback